New York University (NYU) Cancer Institute

New York, New York 10016

0 studies enrolling now · 5 studies all time

What they study most

Carcinoma, Transitional Cell, DLBCL, Diffuse Large B-cell Lymphoma, Grade 3 Follicular Lymphoma, HER2 Positive Breast Cancer, Non-Hodgkin Lymphoma, Renal Pelvis Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urinary Bladder Neoplasms, Urologic Neoplasms, Urothelial Cancer

Studies at this site

• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Running, not enrolling
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer — Completed
• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer — Completed
• A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma — Stopped early